



## PHOST'IN THERAPEUTICS AND THE GIANNI BONADONNA FOUNDATION TO PRESENT FIRST CLINICAL DATA ON PHOX430, A FIRST-IN-CLASS GNT-V INHIBITOR, AT ESMO 2025

Montpellier, France and Milan, Italy – October 2, 2025

**Phost'in Therapeutics, a clinical-stage biotechnology company focused on the development of N-glycosylation inhibitors and the Fondazione Gianni Bonadonna, which provides scientific contribution and independent support, will jointly present a poster on interim clinical data from the PhAST trial at the European Society for Medical Oncology (ESMO) Annual Congress 2025, held October 17–21 in Berlin, Germany.**

---

**Title:** First-in-human clinical trial of the N-acetylglucosaminyltransferase V (GnT-V) inhibitor PhOx430 in patients with Advanced Solid Tumours: the PhAST trial.

**Topic:** Developmental therapeutics

**Number:** 982P

**Authors:** D. Tosi, I. Corbeau, S. Foti, S. Cresta, S. Cavaillon, D. Brambilla, M. Duca, M. Pagano, A. Herrera, L. Clarion, B. Pau, S. Loiseau, G. Brandt, C. Jacquard, M. Guardamagna, A. Fasolo, L. Gianni, G. Del Conte

---

While two expansion cohorts are currently ongoing at the recommended Phase 2 dose and schedule of PhOx430, the poster will present results from the now concluded dose escalation phase of the trial, which enrolled 21 patients with advanced solid tumors. The data include safety, pharmacokinetics, selection of the recommended Phase 2 dose and schedule, pharmacodynamics, biological activity, and predictive biomarkers of response.

PhOx430 is a selective inhibitor of N-acetylglucosaminyltransferase V (GnT-V), a key enzyme in N-glycosylation pathways involved in tumor progression and immune resistance. This is the first clinical evaluation of selective GnT-V inhibition in humans, a breakthrough aligned with the large number of scientific evidence about the role of aberrant glycosylation in cancer development and immune escape. These data also form a critical foundation for considering future combination therapy strategies.

*"The opportunity to present these data at ESMO 2025 highlights both the novelty of the target and the translational significance of our findings" said **Dr. Diego Tosi, MD, PhD, Scientific Coordinator of Gianni Bonadonna Foundation and Head of the Early Clinical Trial Unit at the Institut du Cancer de Montpellier (ICM).** "We look forward to engaging with the oncology community in Berlin and discussing the broader implications of this first-in-human evaluation of GnT-V inhibition."*

**Dr. Alain Herrera, MD, Chief Medical Officer of Phost'in Therapeutics,** added: *"We are excited to share these initial human data at ESMO 2025. Inhibiting GnT-V in patients has never been done before; these results will inform ongoing stage expansions and guide our strategy toward rational combinations."*



The PhAST trial is coordinated under the leadership of Dr. Diego Tosi. The first patient was enrolled at the Institut du Cancer de Montpellier (France). Additional participating sites include IRCCS Ospedale San Raffaele (Milan, Italy), which was involved also from the dose escalation phase, as well as the Istituto Nazionale dei Tumori (Milan, Italy) and IRCCS Reggio Emilia (Italy), both of which have joined for the ongoing cohort expansion phase. The study is managed by Michelangelo Tech Srl (Milan), a contract research organization owned by the Michelangelo Foundation. Phost'in Therapeutics is also supported by Leads to Development (Paris, France), which provides regulatory strategy and operational development expertise.

### **About PhOx430 treatment**

The aberrant, complex and hypersialylated glycosylation of tumor cells is now recognized as a novel immune checkpoint, affecting key membrane receptors and shielding tumor cells to the immune system, via the formation of complex abnormal glycan patterns. PhOx430 targets this aberrant glycosylation directly to the source through selective inhibition of the enzyme GnT-V, inducing simultaneously an anti-cancer immune response and the down regulation of the main receptors implicated in cancer progression. The program has demonstrated a significant antitumoral efficacy in several animal models, associated with a promising safety profile in regulatory preclinical studies. It is the first program from the *Phost'Screen*<sup>TM</sup> platform that combines unique and patented chemical libraries with cutting-edge screening tools to produce selective N-glycosylation inhibitors.

### **About Phost'in Therapeutics**

**Phost'in Therapeutics** is a biotechnology company specialized in the discovery and development of NCEs specifically targeting abnormal pathogenic glycosylation mechanisms. In addition to the clinical development of PhOx430, the company leads upstream research programs in several other diseases using its unique expertise and discovery platform. A spin-off of the academic world, Phost'in possesses, in addition to its own patents, an exclusive license for two families of academic patents owned by CNRS (Centre National de la Recherche Scientifique), ENSCM (École Nationale Supérieure de Chimie de Montpellier), and the Universities of Montpellier, Sorbonne Paris Nord, and Paris-Saclay. Based in Montpellier, France, the company has received the renewed support of France 2030, Bpifrance, the Life Science cluster Eurobiomed, Région Occitanie, and Montpellier Med Vallée. [www.phostin.com](http://www.phostin.com)

Contact: Karine Chorro, CEO & Richard Meadows, CBO - [contact@phostin.com](mailto:contact@phostin.com)

### **About the Gianni Bonadonna Foundation**

Fondazione Gianni Bonadonna was launched to honor and pursue the legacy of Gianni Bonadonna, founding father of modern oncology who developed key new therapies for women with breast cancer and patients with lymphomas. Fondazione Gianni Bonadonna's mission is to promote therapeutic innovation from the earliest phases of research and support the education of new generations of physician-scientists in oncology. [www.fondazionebonadonna.org](http://www.fondazionebonadonna.org)